DJIA 17,001.22 -38.27 -0.22%
NASDAQ 4,538.55 6.45 0.14%
S&P 500 1,988.40 -3.97 -0.20%
market minute promo

22.17 0.15 (0.68%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ACAD $22.17 0.68%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $22.03
Previous Close $22.02
Daily Range $21.84 - $22.28
52-Week Range $15.64 - $32.00
Market Cap $2.2B
P/E Ratio -33.36
Dividend (Yield) $0.00 (0.0%)
Volume 582,731
Average Daily Volume 923,863
Current FY EPS -$0.85





ACADIA Pharmaceuticals, Inc. (ACAD) Description

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. Website:

News & Commentary

Alzheimer's Needs Cures, Not Pyrrhic Victories

As the world's largest Alzheimer's research conference kicks off in Denmark, finding a cure is a long shot at best. Still, there are companies worth watching in this space.

ACADIA Pharmaceuticals' (ACAD) CEO Uli Hacksell on Q2 2014 Results - Earnings Call Transcript

ACADIA Pharmaceuticals (ACAD) Q2 2014 Results - Earnings Call Webcast

Edelman's Perceptive Advisors Buying Amicus Therapeutics Ahead Of Phase III Data Release

ACADIA Pharmaceuticals Announces Stephen Davis As Executive VP, CFO And Chief Business Officer

4 Biotech Stocks Worth A Look Ahead Of FDA Approvals

The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher

ACAD Makes Bullish Cross Above Critical Moving Average

Friday's ETF Movers: FNX, XBI

Are Investors Wrong About Acadia Pharmaceuticals?

Short-sellers have taken a keen interest in clinical-stage biopharma Acadia Pharmaceuticals lately. Here's why.

See More ACAD News...

ACAD's Top Competitors

ACAD $22.17 (0.68%)
Current stock: ACAD
AMGN $132.82 (0.22%)
Current stock: AMGN
GILD $103.96 (1.65%)
Current stock: GILD
BIIB $339.97 (0.39%)
Current stock: BIIB